Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees
© 2022 Inoue et al..
In contrast to a second dose of the SARS-CoV-2 mRNA vaccine, a third dose elicits potent neutralizing activity against the Omicron variant. To address the underlying mechanism for this differential antibody response, we examined spike receptor-binding domain (RBD)-specific memory B cells in vaccinated individuals. Frequency of Omicron-reactive memory B cells increased ∼9 mo after the second vaccine dose. These memory B cells show an altered distribution of epitopes from pre-second memory B cells, presumably due to an antibody feedback mechanism. This hypothesis was tested using mouse models, showing that an addition or a depletion of RBD-induced serum antibodies results in a concomitant increase or decrease, respectively, of Omicron-reactive germinal center (GC) and memory B cells. Our data suggest that pre-generated antibodies modulate the selection of GC and subsequent memory B cells after the second vaccine dose, accumulating more Omicron-reactive memory B cells over time, which contributes to the generation of Omicron-neutralizing antibodies elicited by the third vaccine dose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:220 |
|---|---|
| Enthalten in: |
The Journal of experimental medicine - 220(2023), 2 vom: 06. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inoue, Takeshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 13.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1084/jem.20221786 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350241066 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350241066 | ||
| 003 | DE-627 | ||
| 005 | 20231226044546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1084/jem.20221786 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350241066 | ||
| 035 | |a (NLM)36512034 | ||
| 035 | |a (PII)e20221786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inoue, Takeshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 13.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Inoue et al. | ||
| 520 | |a In contrast to a second dose of the SARS-CoV-2 mRNA vaccine, a third dose elicits potent neutralizing activity against the Omicron variant. To address the underlying mechanism for this differential antibody response, we examined spike receptor-binding domain (RBD)-specific memory B cells in vaccinated individuals. Frequency of Omicron-reactive memory B cells increased ∼9 mo after the second vaccine dose. These memory B cells show an altered distribution of epitopes from pre-second memory B cells, presumably due to an antibody feedback mechanism. This hypothesis was tested using mouse models, showing that an addition or a depletion of RBD-induced serum antibodies results in a concomitant increase or decrease, respectively, of Omicron-reactive germinal center (GC) and memory B cells. Our data suggest that pre-generated antibodies modulate the selection of GC and subsequent memory B cells after the second vaccine dose, accumulating more Omicron-reactive memory B cells over time, which contributes to the generation of Omicron-neutralizing antibodies elicited by the third vaccine dose | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Shinnakasu, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Kawai, Chie |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Sakakibara, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Chikako |e verfasserin |4 aut | |
| 700 | 1 | |a Itoh, Yumi |e verfasserin |4 aut | |
| 700 | 1 | |a Terooatea, Tommy |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Kazuo |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Hashii, Noritaka |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii-Watabe, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Noah S |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuura, Yoshiharu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Hisatake |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Hiraoka, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Teshima, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kurosaki, Tomohiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of experimental medicine |d 1896 |g 220(2023), 2 vom: 06. Feb. |w (DE-627)NLM000005967 |x 1540-9538 |7 nnns |
| 773 | 1 | 8 | |g volume:220 |g year:2023 |g number:2 |g day:06 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1084/jem.20221786 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 220 |j 2023 |e 2 |b 06 |c 02 | ||